Cell
therapy commonly known as regenerative medicine is a medical approach which
involves transfer of autologous or allogeneic cellular material into a patient for
treatment of disease and restore the normal functioning of tissues or organs. However,
cell therapy manufacturing refers to the process of producing therapeutic
cellular products such as dendritic cell vaccines which are used in cell-based
therapies. Cell therapy manufacturing encompasses different approaches and
techniques depending on the specific characteristics of the therapeutic
cellular product and the intended application. Some common type of approaches
comprises of autologous manufacturing, allogeneic manufacturing, centralized
manufacturing, decentralized manufacturing, closed system manufacturing, and
scalable manufacturing. Cell therapy manufacturing is a sequential process
which involves certain steps such as cell sourcing, cell isolation and
purification, cell expansion, cell manipulation and engineering, quality
control, formulation, and administration. United Kingdom has been recognized as
leading hub for life sciences and regenerative medicines, driving the research,
development, and commercialization of cell-based therapies. There are around 21
cell therapy manufacturing organizations established in United Kingdom where 11
of them are dedicated to cell therapy sites, 8 organizations are focused on
gene therapy sites and 7 therapies on multifunctional sites. Selected
organizations which have emerged in accelerating the translation of scientific
knowledge into clinical application includes advanced therapy treatment centers
(ATTCs), cell and gene therapy catapult, and others. Certain factors are
expected to drive the growth of United Kingdom cell therapy manufacturing
market in the forecast period. Increase in prevalence of various chronic
disorders such as cardiovascular diseases, neurological disorders, diabetes,
autoimmune diseases, respiratory disorders, and renal diseases which require
cell-based therapies for proper treatment are expected to register an
impressive growth to United Kingdom cell therapy manufacturing market in
upcoming years. Moreover, growing partnerships and agreements of supreme
pharmaceutical companies in United Kingdom with a vision of combining the
expertise of individual industries is also expected to propel the growth of
cell therapy manufacturing market during forecast period. Rise in investments
made by government for research and development of cell-based therapies is also
a major driver which is expected to boost the growth of United Kingdom cell
therapy manufacturing market in the forecast period.
Download Free Sample Report
Increase
in Prevalence of Chronic Diseases
Chronic
diseases are medical conditions which persists over a long period of time and
require ongoing clinical management. Prevalence of chronic disorders is one of
the major health concerns in United Kingdom. Over 26 million people are
suffering with at least one chronic disease in UK followed by around 10 million
people who are affected by more than two chronic diseases. Some of the leading
chronic ailments which are emerging in United Kingdom includes coronary heart disease,
cancer, stroke, dementia, and diabetes. According to the analysis published
by British Heart Foundation, it has been observed that, there are around 7.6
million people suffering from circulatory heart diseases in UK and 900,000
people are affected by heart attacks which leads to approximately 100,000
hospital admissions per year due to heart attack. Moreover, coronary heart
diseases have further resulted in increased mortality rate in United Kingdom.
Heart and circulatory diseases cause a quarter of all deaths in the UK which is
more than 160,000 deaths each year. Strokes cause around 34,000 deaths every
year and is the leading cause of severe disability in United Kingdom. Another
prominent chronic disorder which is increasing the demand of cell-based
therapies is diabetes. As per the report published by Diabetes UK in 2023,
it has been reported that around 4.3 million people are diagnosed with diabetes
every year in United Kingdom. Registration figures increased by 148,951
instances from 2021 to 2022, where more than 2.4 million people are at high
risk of developing type 2 diabetes. Cell-based therapies have emerged as a
significant method of treating chronic diseases due to their ability of
targeting the underlying causes of the condition. Cell-based therapies involves
the transplantation of stem cells into the affected area which promotes the
repair and tissue regeneration. Moreover, cell therapies also help in
regulating the immune activity by introducing specific cell types. For example,
regulatory T cells can suppress immune responses by reducing inflammation and
autoimmunity in conditions like rheumatoid arthritis or inflammatory bowel
disease. Growing efficiency and modifications in cell-based therapies which are
making them a leading choice for management of chronic diseases are expected to
register an impressive growth to United Kingdom cell therapy manufacturing
market in the forecast period.
Growing
Mergers and Acquisitions
Growing
partnerships and agreements between leading pharmaceutical companies who are
dedicated to combine the expertise of individual industries for improvising
cell-based therapies are also expected to propel the growth of United Kingdom cell
therapy manufacturing market in upcoming years. In 2021, Charles River
Laboratories acquired a cell and gene therapy CDMO Cognate BioServices to
enhance its manufacturing capabilities of cell and gene therapy. Moreover, in
2021, Thermo Fisher Scientific which a renowned medical provider of medical
equipment acquired Henogen S.A. approximately USD 859.7 million which runs a
viral vector manufacturing business in Belgium. This acquisition will increase
its presence in the cell therapy manufacturing market. In 2019, Thermo Fisher
Scientific also merged with Brammer Bio for USD 1.7 billion. Brammer Bio is a
CDMO engaged in viral vector manufacturing for gene and cell therapies.
Furthermore, in January 2022, Century Therapeutics and Bristol-Myers Squibb
signed a license agreement and research collaboration to develop and
commercialize four induced pluripotent stem cell-derived such as engineered
natural killer cell or T-cell programs for solid tumors and hematologic malignancies.
Research
and Development Investments
Cell
and Gene Therapy Catapult is an ultimate initiative taken by United Kingdom research
and innovation for scientific and economic development across the country. The
group aims to highlight the development of UK cell-based therapies with 31%
growth in funds raised by British advanced therapy developers of EUR 1.7
billion. Moreover, United Kingdom’s national innovation agency, Innovate UK
invested up to EUR 16 million for developing UK commercial capacity to
manufacture viral vectors. These viral vectors are used in the production of
clinical cell and gene therapies for management of human disease and disorders.
Furthermore, in 2020, United Kingdom government invested EUR 8.4 million in COVID-19
research projects with an approach to reveal more information about stem cell
therapies as a treatment for disease. Henceforth, increase in investments
Medical Research Council (MRC) for improving human health is further expected
to register a lucrative growth to United Kingdom cell therapy manufacturing
market in the forecast period.
Recent
Developments
- In April 2022, Catalent acquired
Erytech Pharma for its industrial-scale cell therapy manufacturing
facility in Princeton, New Jersey. The deal includes an exclusive
long-term supply partnership that will enable Catalent to promote
ERYTECH's erythrocyte-based therapy Eryaspase (GRASPA) for acute
lymphoblastic leukemia.
- In April 2022, Lonza added
additional integrated capabilities for cell separation, bead removal, and
cell attachment with the release of its second-generation instrument. This
will help the company expand the capabilities of its Cocoon platform to
include magnetic selection capabilities for cell therapy manufacturing.
United
Kingdom cell therapy manufacturing market is segmented based on therapy, source
of cell, scale of operation, source, application, end user, company, and region.
In terms of therapy, the cell therapy manufacturing market is categorized into T-cell
therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies.
Based on, source of cell, United Kingdom cell therapy manufacturing market is
divided into autologous and allogenic. Based on scale of operation, market is
fragmented into preclinical, clinical, and commercial. On the basis of source,
cell therapy manufacturing market is segmented into in-house and contract
manufacturing. Based on application, United Kingdom cell therapy manufacturing
market is categorized into oncology, cardiovascular diseases, orthopedic
diseases, and others. Based on end user, market is fragmented into pharmaceutical
& biotechnology companies, academic & research institutes, and others.
Market
Players
Novartis
Pharmaceuticals UK Ltd., Gilead Sciences, Ltd., Thermo Fisher Scientific Inc.,
Catalent, Inc., Oxford Biomedica plc., Amgen Limited, and Takeda Pharmaceutical
Company Limited are some of the key players in United Kingdom cell therapy
manufacturing market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume in tons,
and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, Volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments Covered
|
Therapy
Source of Cell
Scale of Operation
Source
Application
End User
|
|
Regional
Scope
|
London, East
Anglia, Southwest, Southeast, Scotland, East Midlands, Yorkshire &
Humberside
|
|
Key Companies Profiled
|
Novartis Pharmaceuticals UK Ltd.,
Gilead Sciences, Ltd., Thermo Fisher Scientific Inc., Catalent, Inc., Oxford
Biomedica plc., Amgen Limited, Takeda Pharmaceutical Company Limited
|
|
Customization
Scope
|
10% free
report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to
meet your exact research needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel
through Email (We can also provide the editable version of the report in
PPT/Word format on special request)
|
Report
Scope:
In
this report, United Kingdom cell therapy manufacturing market has been
segmented into following categories, in addition to the industry trends which
have also been detailed below:
- Cell Therapy Manufacturing Market, By Therapy:
o T-Cell Therapies
o Dendritic Cell Therapies
o Tumor Cell Therapies
o Stem Cell Therapies
- Cell Therapy Manufacturing Market, By Source of Cell:
o Autologous
o Allogenic
- Cell
Therapy Manufacturing Market, By Scale of Operation:
o Preclinical
o Clinical
o Commercial
- Cell
Therapy Manufacturing Market, By Source:
o In-House
o Contract Manufacturing
- Cell
Therapy Manufacturing Market, By Application:
o Oncology
o Cardiovascular Diseases
o Orthopedic Diseases
o Others
- Cell
Therapy Manufacturing Market, By End User:
o Pharmaceutical & Biotechnology
Companies
o Academic & Research Institutes
o Others
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies present in United
Kingdom cell therapy manufacturing market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
United
Kingdom cell therapy manufacturing market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]